169 related articles for article (PubMed ID: 35809374)
1. Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology Group.
Hingorani P; Krailo M; Buxton A; Hutson P; Sondel PM; Diccianni M; Yu A; Morris CD; Womer RB; Crompton B; Randall RL; Teot LA; DuBois SG; Janeway KA; Gorlick RG; Isakoff MS
Eur J Cancer; 2022 Sep; 172():264-275. PubMed ID: 35809374
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract][Full Text] [Related]
3. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
Ladenstein R; Pötschger U; Valteau-Couanet D; Luksch R; Castel V; Yaniv I; Laureys G; Brock P; Michon JM; Owens C; Trahair T; Chan GCF; Ruud E; Schroeder H; Beck Popovic M; Schreier G; Loibner H; Ambros P; Holmes K; Castellani MR; Gaze MN; Garaventa A; Pearson ADJ; Lode HN
Lancet Oncol; 2018 Dec; 19(12):1617-1629. PubMed ID: 30442501
[TBL] [Abstract][Full Text] [Related]
4. Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.
Mody R; Yu AL; Naranjo A; Zhang FF; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Hank JA; Felder M; Birstler J; Sondel PM; Asgharzadeh S; Glade-Bender J; Katzenstein H; Maris JM; Park JR; Bagatell R
J Clin Oncol; 2020 Jul; 38(19):2160-2169. PubMed ID: 32343642
[TBL] [Abstract][Full Text] [Related]
5. Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial.
Kushner BH; Cheung IY; Modak S; Basu EM; Roberts SS; Cheung NK
JAMA Oncol; 2018 Dec; 4(12):1729-1735. PubMed ID: 30326045
[TBL] [Abstract][Full Text] [Related]
6. GM-CSF, G-CSF or no cytokine therapy with anti-GD2 immunotherapy for high-risk neuroblastoma.
Mora J; Modak S; Kinsey J; Ragsdale CE; Lazarus HM
Int J Cancer; 2024 Apr; 154(8):1340-1364. PubMed ID: 38108214
[TBL] [Abstract][Full Text] [Related]
7. G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment.
Martinez Sanz P; van Rees DJ; van Zogchel LMJ; Klein B; Bouti P; Olsman H; Schornagel K; Kok I; Sunak A; Leeuwenburg K; Timmerman I; Dierselhuis MP; Kholosy WM; Molenaar JJ; van Bruggen R; van den Berg TK; Kuijpers TW; Matlung HL; Tytgat GAM; Franke K
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049929
[TBL] [Abstract][Full Text] [Related]
8. Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study.
Shusterman S; Naranjo A; Van Ryn C; Hank JA; Parisi MT; Shulkin BL; Servaes S; London WB; Shimada H; Gan J; Gillies SD; Maris JM; Park JR; Sondel PM
Clin Cancer Res; 2019 Oct; 25(20):6044-6051. PubMed ID: 31358541
[TBL] [Abstract][Full Text] [Related]
9. Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma.
Ploessl C; Pan A; Maples KT; Lowe DK
Ann Pharmacother; 2016 May; 50(5):416-22. PubMed ID: 26917818
[TBL] [Abstract][Full Text] [Related]
10. Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology Group.
Arndt CA; Koshkina NV; Inwards CY; Hawkins DS; Krailo MD; Villaluna D; Anderson PM; Goorin AM; Blakely ML; Bernstein M; Bell SA; Ray K; Grendahl DC; Marina N; Kleinerman ES
Clin Cancer Res; 2010 Aug; 16(15):4024-30. PubMed ID: 20576718
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer.
Edelman MJ; Dvorkin M; Laktionov K; Navarro A; Juan-Vidal O; Kozlov V; Golden G; Jordan O; Deng CQ; Bentsion D; Chouaid C; Dechev H; Dowlati A; Fernández Núñez N; Ivashchuk O; Kiladze I; Kortua T; Leighl N; Luft A; Makharadze T; Min Y; Quantin X;
Lung Cancer; 2022 Apr; 166():135-142. PubMed ID: 35278766
[TBL] [Abstract][Full Text] [Related]
12. Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward.
Lagmay JP; Krailo MD; Dang H; Kim A; Hawkins DS; Beaty O; Widemann BC; Zwerdling T; Bomgaars L; Langevin AM; Grier HE; Weigel B; Blaney SM; Gorlick R; Janeway KA
J Clin Oncol; 2016 Sep; 34(25):3031-8. PubMed ID: 27400942
[TBL] [Abstract][Full Text] [Related]
13. Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study.
Gaspar N; Venkatramani R; Hecker-Nolting S; Melcon SG; Locatelli F; Bautista F; Longhi A; Lervat C; Entz-Werle N; Casanova M; Aerts I; Strauss SJ; Thebaud E; Morland B; Nieto AC; Marec-Berard P; Gambart M; Rossig C; Okpara CE; He C; Dutta L; Campbell-Hewson Q
Lancet Oncol; 2021 Sep; 22(9):1312-1321. PubMed ID: 34416158
[TBL] [Abstract][Full Text] [Related]
14. Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission.
Mora J; Castañeda A; Gorostegui M; Santa-María V; Garraus M; Muñoz JP; Varo A; Perez-Jaume S; Mañe S
Pediatr Blood Cancer; 2021 Oct; 68(10):e29121. PubMed ID: 34022112
[TBL] [Abstract][Full Text] [Related]
15. Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation.
Peinemann F; van Dalen EC; Enk H; Tytgat GA
Cochrane Database Syst Rev; 2019 Apr; 4(4):CD012442. PubMed ID: 31016728
[TBL] [Abstract][Full Text] [Related]
16. Dinutuximab for maintenance therapy in pediatric neuroblastoma.
McGinty L; Kolesar J
Am J Health Syst Pharm; 2017 Apr; 74(8):563-567. PubMed ID: 28389455
[TBL] [Abstract][Full Text] [Related]
17. Granulocyte-macrophage colony-stimulating factor in association with high-dose chemotherapy (VETOPEC) for childhood solid tumors: a report from the Australia and New Zealand Children's Cancer Study Group.
McCowage GB; White L; Carpenter P; Lockwood L; Toogood I; Tiedemann K; Shaw PJ
Med Pediatr Oncol; 1997 Aug; 29(2):108-14. PubMed ID: 9180912
[TBL] [Abstract][Full Text] [Related]
18. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2
Chu Y; Nayyar G; Jiang S; Rosenblum JM; Soon-Shiong P; Safrit JT; Lee DA; Cairo MS
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244307
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group.
Kopp LM; Malempati S; Krailo M; Gao Y; Buxton A; Weigel BJ; Hawthorne T; Crowley E; Moscow JA; Reid JM; Villalobos V; Randall RL; Gorlick R; Janeway KA
Eur J Cancer; 2019 Nov; 121():177-183. PubMed ID: 31586757
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma.
Kushner BH; Kramer K; Cheung NK
J Clin Oncol; 2001 Nov; 19(22):4189-94. PubMed ID: 11709561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
